Skip to Main Content

Author Details

Lois Shepherd
Queens University
1991
220
59
PMIDPaper TitleJournal TitlePublished Year
37226534Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.Oncologist2023
37556775Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.J Clin Oncol2023
37695982Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.J Clin Oncol2023
37531248The New NCI Precision Medicine Trials.Clin Cancer Res2023
37319384Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.J Clin Oncol2023
37450521Is There a Doctor in the House?Am J Bioeth2023
36945587Relapse timing is associated with distinct evolutionary dynamics in DLBCL.medRxiv2023
37043087Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6.Support Care Cancer2023
34995105Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).J Clin Oncol2022
35608580Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.JAMA2022
32649577Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.Pharmacogenet Genomics2021
33853037Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.Eur J Cancer2021
33802634Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.Curr Oncol2021
33527137The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.J Natl Cancer Inst2021
33800281A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data.Curr Oncol2021
34615722Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials.Clin Cancer Res2021
34485814Cancer Antigen 15-3/Mucin 1â¿¿Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.JNCI Cancer Spectr2021
34103538Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial.NPJ Breast Cancer2021
33960896Patients with Disorders of Consciousness in the Real World.AJOB Neurosci2021
34172525Who will receive the last ventilator: why COVID-19 policies should not prioritise healthcare workers.J Med Ethics2021
34053112A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.Eur J Haematol2021
34334330A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.Clin Lymphoma Myeloma Leuk2021
34048027Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.Clin Pharmacol Ther2021
32396614The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.Blood Adv2020
31910137The CER Experiment.Am J Bioeth2020
32098767Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.Clin Cancer Res2020
31942813Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and <i>BCL2</i> gene alterations.Leuk Lymphoma2020
32807717Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.Clin Lymphoma Myeloma Leuk2020
32940847Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.Breast Cancer Res Treat2020
32910476Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.Cancer2020
32701512Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.JCI Insight2020
32589730Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.Blood Adv2020
30301414A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 studyâ¿ .Leuk Lymphoma2019
31634905Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial.JAMA2019
31675993Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.Clin Epigenetics2019
31211741Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.Pharmacogenet Genomics2019
31581334What Medical Students Teach: The Healing Skill of Being a Team Player.Hastings Cent Rep2019
31434018Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding.Thromb Res2019
30944027The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.Breast Cancer Res2019
31059586Can we transfuse wisely in patients undergoing chemotherapy for acute leukemia or autologous stem cell transplantation?Transfusion2019
30474129Erosion of informed consent in U.S. research.Bioethics2019
29097500A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.Haematologica2018
30040578Blanket Bans on Therapeutic Abortion and the Responsibilities of Hospitals as Moral Communities.Am J Bioeth2018
30336112Introduction: The Medicalization of Poverty.J Law Med Ethics2018
30336084The Over-Medicalization and Corrupted Medicalization of Abortion and its Effect on Women Living in Poverty.J Law Med Ethics2018
29554282Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.J Natl Cancer Inst2018
29455298Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).Breast Cancer Res Treat2018
29592948<i>TCL1A</i>, a Novel Transcription Factor and a Coregulator of Nuclear Factor <i>κ</i>B p65: Single Nucleotide Polymorphism and Estrogen Dependence.J Pharmacol Exp Ther2018
29128193Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.Clin Breast Cancer2018
29274617Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.Eur J Cancer2018
  • 1 - 50 of 220

Recommended Authors

Felipe Batalini
Mayo Clinic Arizona
Career Start Year 2015
Number of shared co-authors 1
Irbaz Bin Riaz
Mayo Clinic
Career Start Year 2012
Number of shared co-authors 1
Kelley M Kidwell
University of Michigan School of Public Health ann arbor
Career Start Year 2009
Number of shared co-authors 2
Peter Paul Yu
Hartford HealthCare Cancer Institute
Career Start Year 2006
Number of shared co-authors 2
Kathryn J Ruddy
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 18
Nora Horick
Massachusetts General Hospital
Career Start Year 2003
Number of shared co-authors 3
June M McKoy
Feinberg School of Medicine, Northwestern University
Career Start Year 2003
Number of shared co-authors 1
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 10
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 3
Steven Joffe
Medical Ethics and Health Policy, University of Pennsylvania
Career Start Year 1999
Number of shared co-authors 1
Deborah Collyar
Clinical Trials Information Project
Career Start Year 1999
Number of shared co-authors 4
Elizabeth Garrett-Mayer
Center for Research and Analytics, American Society of Clinical Oncology
Career Start Year 1997
Number of shared co-authors 6
David Elashoff
David Geffen School of Medicine at University of California los angeles
Career Start Year 1997
Number of shared co-authors 1
Jeffrey Peppercorn
Massachusetts General Hospital, Harvard Medical School
Career Start Year 1993
Number of shared co-authors 5
Madhu Mazumdar
Icahn School of Medicine at Mount Sinai
Career Start Year 1992
Number of shared co-authors 2
Borko Jovanovic
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Career Start Year 1991
Number of shared co-authors 0
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 1
Peter W Marks
Center for Biologics Evaluation and Research
Career Start Year 1988
Number of shared co-authors 0
Mark Lawler
Queens University Belfast Belfast
Career Start Year 1988
Number of shared co-authors 2
Motomi Mori
St Jude Children's Research Hospital.
Career Start Year 1988
Number of shared co-authors 1
Charles L Bennett
University of South Carolina
Career Start Year 1986
Number of shared co-authors 1
Paul Harnett
Westmead Clinical School, University of Sydney
Career Start Year 1986
Number of shared co-authors 5
Benjamin Djulbegovic
Medical University of South Carolina
Career Start Year 1985
Number of shared co-authors 2
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 7
Brad H Pollock
University of California davis
Career Start Year 1983
Number of shared co-authors 1
Donald A Berry
MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 15
Jonathan Kimmelman
McGill University
Career Start Year 1977
Number of shared co-authors 2
David A Schoenfeld
Mass General Hospital
Career Start Year 1977
Number of shared co-authors 1
Judith D Goldberg
NYU Grossman School of Medicine
Career Start Year 1974
Number of shared co-authors 1

Collaborators

Kathleen I Pritchard
UCL Great Ormond Street Institute of Child Health, University College London
Co-authored papers 65
James N Ingle
Mayo Clinic
Co-authored papers 40
Mark N Levine
Juravinski Hospital and Cancer Center
Co-authored papers 24
Matthew J Ellis
Co-authored papers 16
Richard M Weinshilboum
Mayo Clinic
Co-authored papers 13
Liewei Wang
Mayo Clinic
Co-authored papers 12
Matthew P Goetz
Mayo Clinic
Co-authored papers 11
Dawn L Hershman
Co-authored papers 9
Michiaki Kubo
Co-authored papers 8
Nancy E Davidson
Co-authored papers 8
Ingrid A Mayer
Vanderbilt University Medical Center
Co-authored papers 8
Keyue Ding
Queen's University
Co-authored papers 8
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 6
David W Scott
University of British Columbia
Co-authored papers 6
John M S Bartlett
University of Edinburgh
Co-authored papers 6
Vered Stearns
Co-authored papers 6
Larry Norton
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Co-authored papers 5
Alison F Munro
Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital
Co-authored papers 4
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 4
Alexander Keith Stewart
Co-authored papers 4
Samuel Leung
University of British Columbia
Co-authored papers 4
Dennis C Sgroi
Co-authored papers 3
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 3
Samuel Aparicio
University of British Columbia
Co-authored papers 3
Ryan D Morin
Simon Fraser University
Co-authored papers 3
Irene L Andrulis
University of Toronto
Co-authored papers 3
Michael J O'Connell
NSABP Foundation
Co-authored papers 3
Marco A Marra
University of British Columbia
Co-authored papers 3
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Co-authored papers 3
Release 1.2